Product Data Sheet

Sparfloxacin

Molecular Weight: 392.4

Target: Bacterial; Antibiotic

Pathway: Anti-infection

Storage: 4°C, protect from light

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro 0.1 M NaOH: 50 mg/mL (127.42 mM; ultrasonic and adjust pH to 11 with NaOH)

DMSO: 3.33 mg/mL (8.49 mM; Need ultrasonic)

H₂O: < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5484 mL	12.7421 mL	25.4842 mL
	5 mM	0.5097 mL	2.5484 mL	5.0968 mL
	10 mM	0.2548 mL	1.2742 mL	2.5484 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Sparfloxacin (CI-978) is a fluoroquinolone antibiotic, shows broad and potent antibacterial activity $^{[1]}$.
IC ₅₀ & Target	Quinolone
In Vitro	Sparfloxacin (CI-978) shows broad and potent antibacterial activity. Its MICs for 90% of the strains tested are 0.1 to 0.78 μ g/ml against gram-positive organisms, such as members of the genera Staphylococcus , Streptococcus and Enterococcus , and 0.0125 to 1.56 μ g/ml against gram-negative organisms, such as members of the family Enterobacteriaceae and the genera Pseudomona . Its MICs are 0.025 to 0.78 μ g/ml against glucose nonfermenters, 0.2 to 0.78 μ g/ml against anaerobes, 0.0125 to 0.05 μ g/ml against Legionella. Sparfloxacin (CI-978) showed good oral efficacy against systemic infections with Staphylococcus aureus , Streptococcus pyogenes , Streptococcus pneumoniae , Escherichia coli , and Pseudomonas aeruginosa in mice ^[1] . Sparfloxacin targets DNA gyrase and inhibits DNA synthesis ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Nakamura, S., et al., In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother, 1989. 33(8): p. 1167-73.
[2]. Pan, X.S. and L.M. Fisher, Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother, 1997. 41(2): p. 471-4.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fa

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com